Format

Send to:

Choose Destination
See comment in PubMed Commons below
Biochim Biophys Acta. 2012 Aug;1826(1):23-31. doi: 10.1016/j.bbcan.2012.03.002. Epub 2012 Mar 13.

E-cadherin's dark side: possible role in tumor progression.

Author information

  • 1Department of Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

Abstract

In the context of cancer, E-cadherin has traditionally been categorized as a tumor suppressor, given its essential role in the formation of proper intercellular junctions, and its downregulation in the process of epithelial-mesenchymal transition (EMT) in epithelial tumor progression. Germline or somatic mutations in the E-cadherin gene (CDH1) or downregulation by epigenetic mechanisms have been described in a small subset of epithelial cancers. However, recent evidence also points toward a promoting role of E-cadherin in several aspects of tumor progression. This includes preserved (or increased) E-cadherin expression in microemboli of inflammatory breast carcinoma, a possible "mesenchymal to epithelial transition" (MET) in ovarian carcinoma, collective cell invasion in some epithelial cancers, a recent association of E-cadherin expression with a more aggressive brain tumor subset, as well as the intriguing possibility of E-cadherin involvement in specific signaling networks in the cytoplasm and/or nucleus. In this review we address a lesser-known, positive role for E-cadherin in cancer.

Copyright © 2012 Elsevier B.V. All rights reserved.

PMID:
22440943
[PubMed - indexed for MEDLINE]
PMCID:
PMC3362679
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk